$RAPT
RAPT Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062471 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.453M $6.900M
YoY Change 29.66% 35.85%
% of Gross Profit
Research & Development $26.76M $27.02M
YoY Change 37.58% 62.79%
% of Gross Profit
Depreciation & Amortization $323.0K $320.0K
YoY Change 28.17% 23.08%
% of Gross Profit
Operating Expenses $33.22M $33.92M
YoY Change 35.96% 56.47%
Operating Profit -$33.92M
YoY Change 56.47%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.341M $2.548M
YoY Change 58.18% 475.17%
Pretax Income -$30.88M -$31.37M
YoY Change 34.53% 47.73%
Income Tax
% Of Pretax Income
Net Earnings -$30.88M -$31.37M
YoY Change 34.53% 47.73%
Net Earnings / Revenue
Basic Earnings Per Share -$0.82
Diluted Earnings Per Share -$0.80 -$0.82
COMMON SHARES
Basic Shares Outstanding 34.40M 34.36M
Diluted Shares Outstanding 38.36M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $158.9M $184.8M
YoY Change -36.22% -5.44%
Cash & Equivalents $47.48M $54.14M
Short-Term Investments $111.4M $130.6M
Other Short-Term Assets $2.920M $2.400M
YoY Change -19.47% -2.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $161.8M $187.1M
YoY Change -35.98% -5.44%
LONG-TERM ASSETS
Property, Plant & Equipment $2.448M $2.704M
YoY Change -3.58% -1.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.871M $4.207M
YoY Change -4.09% 36.99%
Total Long-Term Assets $11.55M $12.58M
YoY Change -14.56% 8.52%
TOTAL ASSETS
Total Short-Term Assets $161.8M $187.1M
Total Long-Term Assets $11.55M $12.58M
Total Assets $173.3M $199.7M
YoY Change -34.89% -4.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.176M $5.297M
YoY Change 53.82% 31.02%
Accrued Expenses $14.10M $14.11M
YoY Change 62.93% 71.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.84M $21.85M
YoY Change 53.52% 57.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.458M $5.100M
YoY Change -34.62% -19.25%
Total Long-Term Liabilities $4.458M $5.100M
YoY Change -34.62% -19.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.84M $21.85M
Total Long-Term Liabilities $4.458M $5.100M
Total Liabilities $26.29M $26.92M
YoY Change 24.95% 33.38%
SHAREHOLDERS EQUITY
Retained Earnings -$484.7M -$453.8M
YoY Change 31.75% 31.56%
Common Stock $631.6M $626.7M
YoY Change 3.02% 17.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $147.0M $172.8M
YoY Change
Total Liabilities & Shareholders Equity $173.3M $199.7M
YoY Change -34.89% -4.66%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$30.88M -$31.37M
YoY Change 34.53% 47.73%
Depreciation, Depletion And Amortization $323.0K $320.0K
YoY Change 28.17% 23.08%
Cash From Operating Activities -$27.75M -$21.88M
YoY Change 21.47% 27.59%
INVESTING ACTIVITIES
Capital Expenditures $67.00K $70.00K
YoY Change 36.73% -186.42%
Acquisitions
YoY Change
Other Investing Activities $20.71M $25.81M
YoY Change -150.23% -247.33%
Cash From Investing Activities $20.64M $25.74M
YoY Change -150.01% -246.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 458.0K 110.0K
YoY Change -99.39% -97.91%
NET CHANGE
Cash From Operating Activities -27.75M -21.88M
Cash From Investing Activities 20.64M 25.74M
Cash From Financing Activities 458.0K 110.0K
Net Change In Cash -6.657M 3.970M
YoY Change -159.23% -113.46%
FREE CASH FLOW
Cash From Operating Activities -$27.75M -$21.88M
Capital Expenditures $67.00K $70.00K
Free Cash Flow -$27.82M -$21.95M
YoY Change 21.5% 28.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7923000
dei Entity Central Index Key
EntityCentralIndexKey
0001673772
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38997
dei Entity Registrant Name
EntityRegistrantName
RAPT Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3313701
dei Entity Address Address Line1
EntityAddressAddressLine1
561 Eccles Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
489-9000
dei Security12b Title
Security12bTitle
Common Stock $0.0001 par value per share
dei Trading Symbol
TradingSymbol
RAPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34396212
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54135000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38946000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
130642000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
210122000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2361000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3626000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
187138000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
252694000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2704000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2539000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5672000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6940000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4207000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4036000
CY2023Q3 us-gaap Assets
Assets
199721000
CY2022Q4 us-gaap Assets
Assets
266209000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5297000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3365000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14109000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8656000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2390000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
53000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
32000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
21849000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14224000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5072000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6819000
CY2023Q3 us-gaap Liabilities
Liabilities
26921000
CY2022Q4 us-gaap Liabilities
Liabilities
21043000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
626724000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
613073000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-121000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-26000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453806000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367884000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
172800000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245166000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
199721000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266209000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1527000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27022000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16599000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74238000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47628000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6897000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5079000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19607000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15263000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
33919000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
21678000
us-gaap Operating Expenses
OperatingExpenses
93845000
us-gaap Operating Expenses
OperatingExpenses
62891000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33919000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21678000
us-gaap Operating Income Loss
OperatingIncomeLoss
-93845000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61364000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2548000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
443000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
477000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-31371000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21235000
us-gaap Net Income Loss
NetIncomeLoss
-85922000
us-gaap Net Income Loss
NetIncomeLoss
-60887000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
366000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-655000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
715000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
560000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-962000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31312000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20943000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86017000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61134000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.82
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.82
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.63
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.24
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.24
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.93
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.93
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38358032
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38358032
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33684261
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33684261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38322773
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38322773
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31481948
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31481948
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245166000
CY2023Q1 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
116000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4094000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
365000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-29271000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
220470000
CY2023Q2 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
767000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4239000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-655000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
136000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25280000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
199677000
CY2023Q3 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
106000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4329000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
59000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-31371000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
172800000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186380000
CY2022Q1 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
132000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2702000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-201000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-710000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20468000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
167835000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
49784000
CY2022Q2 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
654000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2672000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
550000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-178000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19184000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
202133000
CY2022Q3 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
272000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2865000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
366000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21235000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
189306000
us-gaap Profit Loss
ProfitLoss
-85922000
us-gaap Profit Loss
ProfitLoss
-60887000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4512000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-359000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
893000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
795000
us-gaap Share Based Compensation
ShareBasedCompensation
12662000
us-gaap Share Based Compensation
ShareBasedCompensation
8239000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
655000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-715000
rapt Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1751000
rapt Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1282000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1094000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-712000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7406000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3973000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1527000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2011000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1583000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69294000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47922000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
106238000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
112718000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
190790000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
109294000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1058000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
796000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
83494000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4220000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49784000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
989000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1058000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
989000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55821000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15189000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3679000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38946000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24027000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54135000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27706000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6585000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of the Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RAPT Therapeutics, Inc. (“RAPT” or the “Company”) is a clinical stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
184898000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2023Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2023-01-01
CY2023Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
126000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
184777000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
54135000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
54135000
CY2023Q3 rapt Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
130763000
CY2023Q3 rapt Marketable Securities At Unrealized Gains
MarketableSecuritiesAtUnrealizedGains
5000
CY2023Q3 rapt Marketable Securities At Unrealized Losses
MarketableSecuritiesAtUnrealizedLosses
126000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
130642000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
249461000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
45000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
726000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
248780000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
38658000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
38658000
CY2022Q4 rapt Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
210803000
CY2022Q4 rapt Marketable Securities At Unrealized Gains
MarketableSecuritiesAtUnrealizedGains
45000
CY2022Q4 rapt Marketable Securities At Unrealized Losses
MarketableSecuritiesAtUnrealizedLosses
726000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
210122000
rapt Marketable Securities Impairment Loss
MarketableSecuritiesImpairmentLoss
0
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
126718000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
3924000
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
130642000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11770000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10788000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9066000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8249000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2704000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2539000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
CY2023Q3 rapt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
7914000
CY2022Q4 rapt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3473000
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
5508000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
4618000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
531000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
327000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
156000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
238000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14109000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8656000
CY2018Q2 rapt Additional Square Feet Area Of Laboratory And Office Facilities Under Lease
AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
6378
CY2018Q2 rapt Increased Area Of Leased Premises
IncreasedAreaOfLeasedPremises
36754
CY2018Q2 rapt Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
2026-11
CY2015Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2015Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q4 rapt Operating Lease Expiration Year
OperatingLeaseExpirationYear
2025-07
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P6M
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33684261
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33684261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38322773
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38322773
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31481948
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
696000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2855000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2662000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2137000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8350000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
888000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7462000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5672000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2390000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5072000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7462000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2023Q3 us-gaap Lease Cost
LeaseCost
700000
us-gaap Lease Cost
LeaseCost
2100000
us-gaap Operating Lease Payments
OperatingLeasePayments
2000000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0822
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31481948
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11602947
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4329000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2865000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12662000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8239000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
32700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-31371000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21235000
us-gaap Net Income Loss
NetIncomeLoss
-85922000
us-gaap Net Income Loss
NetIncomeLoss
-60887000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38358032
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38358032
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.93
CY2023Q3 rapt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
4000000
CY2022Q3 rapt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
4000000
rapt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
4000000
rapt Pre Funded Warrants To Purchase Common Stock
PreFundedWarrantsToPurchaseCommonStock
4000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4119868
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3016697

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-062471-index-headers.html Edgar Link pending
0000950170-23-062471-index.html Edgar Link pending
0000950170-23-062471.txt Edgar Link pending
0000950170-23-062471-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rapt-20230930.htm Edgar Link pending
rapt-20230930.xsd Edgar Link pending
rapt-ex31_1.htm Edgar Link pending
rapt-ex31_2.htm Edgar Link pending
rapt-ex32_1.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rapt-20230930_def.xml Edgar Link unprocessable
rapt-20230930_lab.xml Edgar Link unprocessable
rapt-20230930_cal.xml Edgar Link unprocessable
rapt-20230930_pre.xml Edgar Link unprocessable
rapt-20230930_htm.xml Edgar Link completed